Sort
10,766 grants matching “checkpoint inhibitor”
Identification of genetic interactors of Brca2
$1,064,216Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Targeting the cGAS/STING Pathway to Overcome Resistance to Immune Checkpoint Inhibitors in PTEN-deficient Prostate Cancer
$1,063,904Akash Patnaik · University Of Chicago · R01 · FY2025 · CA
Immunotherapeutic Interventions of AIDS and Cancer
$1,062,472Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation
$1,062,441Robert J Coffey · Vanderbilt University Medical Center · R35 · FY2024 · CA
Towards targeting the lymphoma microenvironment
$1,062,000Hans-Guido Wendel · Sloan-Kettering Inst Can Research · R35 · FY2021 · CA
Towards targeting the lymphoma microenvironment
$1,062,000Hans-Guido Wendel · Sloan-Kettering Inst Can Research · R35 · FY2025 · CA
Clinical Evaluation of a Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitors for Triple Negative Breast Cancer
$1,061,403Christopher D Pack · Metaclipse Therapeutics Corporation · R44 · FY2021 · CA
Identification of radiosensitizers for prostate cancer
$1,061,377Travis Stracker · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting
$1,059,896Song Yao · Roswell Park Cancer Institute Corp · UG3 · FY2021 · CA
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$1,058,087Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Initiation of DNA Replication in Mammalian Cells
$1,057,445Mirit Aladjem · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Bladder Cancer Program
$1,057,180Andrea Apolo · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Preclinical drug development in pancreas cancer
$1,056,492Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
Determinants of response to cancer immunotherapy
$1,055,838Lawrence Fong · Fred Hutchinson Cancer Center · R35 · FY2025 · CA
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,055,681Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Liver Cancer Program
$1,051,369Anuradha Budhu · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
$1,049,779Thomas M Roberts · Dana-Farber Cancer Inst · R35 · FY2020 · CA
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
$1,049,779Thomas M Roberts · Dana-Farber Cancer Inst · R35 · FY2025 · CA
Maximizing the Effectiveness of PI3K Inhibitors in the Treatment of Pten null Cancers
$1,049,779Thomas M Roberts · Dana-Farber Cancer Inst · R35 · FY2021 · CA
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy
$1,049,717Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · CA
Targeting Genetic and Metabolic Alterations in Distinct Subtypes of RCC
$1,048,777Ramaprasad Srinivasan · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
DNA Repair, Cell Cycle Checkpoints and Apoptosis as Targets for Anticancer Drugs
$1,047,789Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Cell Cycle Regulation In Oogenesis
$1,047,257Mary A Lilly · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2015 · HD
Activating Cell Death Pathways in Breast Cancer Cells
$1,045,773Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2023 · CA
Vaccine and immunotherapy strategies for cancer and viruses causing cancer
$1,042,696Jay A Berzofsky · Division Of Clinical Sciences - Nci · ZIA · FY2021 · CA